New combo therapy aims to outsmart resistant breast cancer
NCT ID NCT03959891
Summary
This early-stage trial is testing whether adding an experimental drug called ipatasertib to standard hormone therapies can help control metastatic breast cancer that has stopped responding to previous treatments. The study will enroll 77 postmenopausal women to determine if the combination is safe and shows signs of slowing cancer growth. Researchers hope blocking the Akt enzyme in cancer cells may overcome resistance to standard medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.